Progyny Inc.
PGNY | NASDAQ
$26.49
-$0.37 (-1.38%)
Sep 22, 2026, 11:47 AM ET · Market open
Company Profile
Progyny, Inc. functions as a benefits management corporation, dedicated to providing specialized solutions for fertility and broader family-building initiatives to employers throughout the United States. Its core fertility offering is characterized by a distinctive benefits plan architecture, paired with personalized, white-glove member support services and access to a meticulously chosen network of top-tier fertility specialists. Additionally, the company presents Progyny Rx, an all-encompassing pharmacy benefits solution that ensures its members can readily acquire the essential medications for their treatments. Moreover, Progyny facilitates employer-sponsored reimbursement programs to support surrogacy and adoption journeys. The company, which was established in 2008 and has its main offices in New York City, previously operated as Auxogyn, Inc. before adopting the Progyny, Inc. moniker in 2015.
Key Executives
| Name | Position |
|---|---|
| Peter Anevski | Chief Executive Officer & Director |
| Mark S. Livingston | Chief Financial Officer |
| Melissa Cummings | Chief Operating Officer |
| Risa Fisher | Chief Marketing Officer |
| Steven Leist | Chief Technology Officer |
| Allison Swartz | Executive Vice President, General Counsel & Secretary |
| Cassandra Pratt | Chief Human Resources Officer |
| David J. Schlanger | Executive Chairman |
| Geoffrey Clapp | Chief Product Officer |
| James Hart | Vice President of Investor Relations |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Sep 04, 2026 | 4 | Filing |
| Sep 01, 2026 | 4 | Filing |
| Aug 07, 2026 | 10-Q | Quarterly Report |
| Aug 06, 2026 | 8-K | Current Report |
| Aug 06, 2026 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Jul 16, 2026 | 4 | Filing |
| Jun 23, 2026 | 4 | Filing |
| Jun 08, 2026 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Jun 05, 2026 | 4 | Filing |
| Jun 05, 2026 | 4 | Filing |
Progyny Inc.
| Country | United States |
| IPO Date | Oct 24, 2019 |
| Industry | Medical - Healthcare Plans |
| Sector | Healthcare |
| Employees | 846 |
| CEO | Pete Anevski |
Contact Details
1359 Broadway New York City,
New York 10018 United States
Stock Details
| Ticker Symbol | PGNY |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001551306 |
| CUSIP Number | 74340E103 |
| ISIN Number | US74340E1038 |
| SIC Code | 8090 |
Recent News
- 4 days ago / zacks.comPGNY vs. CRL: Which Stock Is the Better Value Option?
- 5 days ago / seekingalpha.comProgyny: Best-In-Class And Likely To Exceed Analyst Estimates In 2027
- 13 days ago / zacks.comWall Street Analysts Predict a 25.23% Upside in Progyny (PGNY): Here's What You Should Know
- 19 days ago / globenewswire.comProgyny, Inc. to Present at the Wells Fargo Healthcare Conference
- 27 days ago / defenseworld.netProgyny, Inc. (NASDAQ:PGNY) Receives Consensus Recommendation of “Moderate Buy” from Analysts
- 1 month ago / gurufocus.comProgyny Inc (PGNY) Stock Down 4.6% -- Now Undervalued? GF Score: 93/100
- 2 months ago / globenewswire.comProgyny, Inc. to Present at the Canaccord Genuity Annual Growth Conference
- 2 months ago / marketbeat.comProgyny Q2 Earnings Call Highlights
- 2 months ago / seekingalpha.comProgyny, Inc. (PGNY) Q2 2026 Earnings Call Transcript
- 2 months ago / zacks.comProgyny (PGNY) Reports Q2 Earnings: What Key Metrics Have to Say
Add to Watchlist
Select watchlists to add or remove PGNY